Aurobindo receives 2 more USFDA approvals

RELATED NEWS 3 more European buys for Aurobindo Pharma Aurobindo Pharma acquires Pharmacin International B.V European acquisitions to boost Aurobindo's revenues Aurobindo Pharma buys Dutch firm Pharmacin ALSO READ See latest News about Aurobindo Pharm See previous management interviews See what other Experts & Brokerages are saying about Aurobindo Pharm Aurobindo Pharm BSE | NSE 10/02/12 Are Mutual Funds betting on Aurobindo Pharm?

Aurobindo Pharma Limited is pleased to announce that the company has received two more approvals from the US FDA for Bisoprolol 5 mg, 10 mg & Amoxicillin oral suspension 200mgml, and 400mgml. This is Aurobindo's 34th & 35th generic approval given by US FDA respectively.

 

Amoxicillin oral suspension is a Beta-lactam antibiotic used often in treating respiratory infections. GSK is the inventor of this antibiotic and is marketed under the brand name Amoxil.

 

Bisoprolol is a beta1-selective (cardioselective) adrenoceptor-blocking agent. It belongs to the group called Beta-blockers. Bisoprolol tablets are employed in managing cardiovascular diseases such as hypertension, coronary heart diseases and arrhythmias etc. Bisoprolol is the original product of MS Duramed Pharms Barr and is known as Zebeta.

 

These two products currently command a market size of USD 100 mio (appx) in USA which enhances Aurobindo's opportunity in Generics business.

 

Sourced From: Aurobindo Pharma Limited